FDA lifts a hold on Flexion pain drug; GW Pharma preps study for autism;

@FierceBiotech: From FierceBiotechIT: Texas' $3B cancer agency makes computational biology a priority. Article | Follow @FierceBiotech

@JohnCFierce: I wonder if someone would pay me $3.5B for Uncle John's Quiet Time Elixir. (Nyquil and bourbon). $AVNR. | Follow @JohnCFierce

@DamianFierce: Tim Duncan donated $247K to help sequence the genomes of 1,000 cancer patients and publicize the results. Article | Follow @DamianFierce

> Burlington, MA-based Flexion ($FLXN) says that the FDA has lifted its clinical hold on its lead pain drug candidate, FX006. The biotech reports that had completed the FDA's "requested testing and investigation related to what was originally reported as a single case of septic arthritis of the knee." The removal of the regulatory obstacle clears the way for investigators to resume a Phase IIb study and launch Phase III in early 2015. Flexion shares were up about 6% this morning. Release

> GW Pharmaceuticals is planning to test its cannabis-based drugs on severe autism. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic gets EU regulatory green light for $43 billion merger with Covidien. Article | Follow @FierceMedDev

@EmilyWFierce: Roche acquires prenatal diagnostics outfit Ariosa. Press release | Follow @EmilyWFierce

> Medtronic sells $17B in bonds to fund Covidien buy. Story

> Masimo wireless, wearable patient monitor cleared by FDA. More

> Edison Nation and Mount Sinai team up for device innovation. Article

> FDA approves Animas insulin pump, continuous glucose monitor combo device. Report

Pharma News

@FiercePharma: ICYMI yesterday: Reuters: In Fresenius, Danone could lose second suitor for nutrition unit. Item | Follow @FiercePharma

@CarlyHFierce: Reuters: In Fresenius, Danone could lose second suitor for nutrition unit. More | Follow @CarlyHFierce

> BMS makes cuts in China, reports say up to 1,000. Article

> Otsuka spends $3.5B for Avanir--and patent-cliff protection. Story

> NICE changes its attitude on Roche's Gazyvaro. More

Biotech Research News

> New structural biology software tackles viruses and bacteria. Story

> 8-year study highlights role of a key protein in cardiomyopathy. More

> Binge drinking 'cure' in rats sparks a debate over animal study. Story

> Cell research at Brigham & Women's points to a new drug target for fibrosis. Report

> Harvard, MIT teams identify a 'pre-malignant' phase for blood cancers. Article

Pharma Manufacturing News

> Lyophilization market forecast to double in size by 2020. Article

> FDA slaps Dr. Reddy's with a Form 483. Report

> Eisai opens new plants targeting Asia and Europe. More

> Italy clears Novartis vaccine manufacturing in deaths following vaccinations. Story

> Recipharm expands footprint, buys Flamel facility in France for $13.2M. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.